{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-004017","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.936889+00:00","generated_at":"2026-06-04T13:07:31.790154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024","bullets":["FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).","Cash and investments $62.9M; SG&A down 16% to support cost containment.","Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.","PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.","Recorded $10.4M goodwill impairment charge for Exemplar subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-004017","json":"https://secwatch.observer/filing/0000950103-24-004017.json","markdown":"https://secwatch.observer/filing/0000950103-24-004017.md","text":"https://secwatch.observer/filing/0000950103-24-004017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/0000950103-24-004017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/dp208564_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:07:31.790154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c097e744caa4bfbaf4c0ad4a5b16669ae98a5c5b","claim":"PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2024, reporting its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/0000950103-24-004017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}